Research and Markets (http://www.researchandmarkets.com/research/mf3rwt/investigation)
has announced the addition of the "Investigation
Report on China Epoetin Alfa Market, 2009-2018" report to their
Epoetin alfa refers to erythropoietin (EPO), a hormone-like substance
secreted by kidney and liver that stimulates erythropoiesis. Indications
of EPO approved in China are renal anemia, anemia after chemotherapy and
surgery perioperative red blood cell mobilization.
The ratio between EPO used in renal dialysis and in chemotherapy is 3:1.
Growth rate of EPO used in chemotherapy is about 20% to 25%, which is
higher than that of renal dialysis. However, in the international
market, more EPO is used in anemia after chemotherapy than in renal
dialysis. This indicates huge market space for EPO used in anemia after
chemotherapy in China.
Originall developed by Amgen Inc., epoetin alfa was approved to the
U.S. in June 1989 by FDA with the trade name ""Epogen"". It is sold in
over 40 countries now. Amgen is the only authorized product sold in the
U.S. hemodialysis market. However, in other indications' market in the
U.S., due to financial shortage, Amgen gave the marketing right of
Epogen to Kirin-Amgen, Inc. (joint venture of Amgen and Kirin). The
company then authorized Ortho Pharmaceutical Corporation of Johnson &
Johnson to sell the product with the brand name ""Procrit"". In other
countries including Chinese mainland, Taiwan and Japan, the drug is sold
by Kirin Inc. and Johnson & Johnson with the trade names ""Espo"" and
""Eprex"" respectively. Both the companies are authorized by Kirin-Amgen.
Key Topics Covered:
1 Relevant Concepts of Epoetin Alfa
2 Market Overview of Epoetin Alfa in China
3 Investigation on Sales Value of Epoetin Alfa in China, 2009-2013
4 Investigation on Market Share of Major Epoetin Alfa Manufacturers in
5 Investigation on Market Size of Epoetin Alfa by Dosage Form in China,
6 Reference Price of Epoetin Alfa Produced by Different Enterprises in
China Hospital Market
7 Analysis on Major Epoetin Alfa Manufacturers in China, 2009-2013
8 Prospect of China Epoetin Alfa Market, 2014-2018
- Shenyang Sunshine Pharmaceutical Co., Ltd.
- Kirin Brewery Company, Limited
- NCPC GeneTech Biotechnology development Co., Ltd.
- Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
- Beijing Sihuan Biopharmaceutical Co., Ltd.
- Shanghai Chemo Wanbang Biopharmaceutical Co., Ltd.
- Harbin Pharmaceutical Group Bio-Engineering Co., Ltd.
- Shandong Kexing Bioproducts Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/mf3rwt/investigation
[ Back To NFVZone's Homepage ]